Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Combined pre- and postcapillary PH associated with worst survival in chronic kidney disease

21 Dec 2019

Chronic kidney disease (CKD) patients referred for right heart catheterization commonly have pulmonary hypertension (PH), with the combination of pre- and postcapillary PH subtypes associated with worst survival, a study reports.

Researchers looked at 12,618 patients with a right heart catheterization. Of these, 73.4 percent of patients with CKD and 56.9 percent of those without CKD presented with PH. The most common PH subtypes were isolated postcapillary PH (39.0 percent) and combined pre- and postcapillary PH (38.3 percent) in the CKD cohort, and precapillary PH (35.9 percent) in the non-CKD cohort.

The associations of mortality with mean pulmonary artery pressure, pulmonary capillary wedge pressure and right atrial pressure were similar in both the CKD and non-CKD cohorts.

On multivariable Cox proportional hazards analysis, precapillary PH conferred the highest mortality risk among patients in the non-CKD cohort (hazard ratio [HR], 2.27, 95 percent confidence interval [CI], 2.00–2.57).

In contrast, combined pre- and postcapillary PH was associated with the highest mortality risk in the CKD cohort. The HRs for mortality according to glomerular filtration rate categories were as follows: 1.89 (95 percent CI, 1.57–2.28) in G3a, 1.87 (95 percent CI, 1.52–2.31) in G3b, 2.13 (95 percent CI, 1.52–2.97) in G4 and 1.63 (95 percent CI, 1.12–2.36) in G5/G5D.

The study had several limitations, such as those inherent in its observational nature. Serum creatinine data in the 6 months preceding catheterization might not reflect true baseline CKD. Finally, the findings might not be generalizable to the general CKD population as the cohort included only those referred for right heart catheterization.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.